Physician profile
Nadia Mcfarlane
NPI 1619175239
$19,823.17
in general payments reported to CMS, 2019-2025
23 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.20 · 2021: $50.83 · 2022: $271 · 2023: $616 · 2024: $409 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $17K · Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $17,410.00 |
| Food and Beverage | $2,043.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $17,473.45 | 2023-2025 | Neurostar Tms Therapy System |
| Corium, LLC | $293.75 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $249.72 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $246.01 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.78 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $143.69 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $125.62 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $120.17 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $118.62 | 2022-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $109.74 | 2023-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $108.38 | 2025 | Auvelity |
| Alkermes, INC. | $93.52 | 2019-2023 | Aristada, Lybalvi |
| Collegium Pharmaceutical, INC. | $85.44 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $75.75 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $75.30 | 2024-2025 | Ingrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $66.84 | 2022-2025 | Rexulti |
| Abbvie INC. | $51.84 | 2023-2025 | |
| Brainsway USA INC | $50.83 | 2021 | |
| Tris Pharma INC | $44.27 | 2025 | Dyanavel Xr, Onyda Xr |
| Teva Pharmaceuticals USA, INC. | $40.47 | 2023-2024 | Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $29.16 | 2022-2023 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $25.71 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.11 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.